TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in Cancers reporting preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study found that TTX-MC138, when administered systemically, accumulated in metastatic bone lesions, reduced expression of microRNA-10b (miR-10b), and increased expression of the downstream tumor-suppressor target HOXD10. These molecular changes were associated with significant survival benefits in treated animals compared with controls. Importantly, repeated dosing was well tolerated, with no observed systemic toxicity.
The findings are a crucial step in validating TransCode's innovative approach to targeting miR-10b, a well-documented biomarker of metastasis. By using its proprietary oligonucleotide nanotechnology, the company aims to inhibit this microRNA, which is overexpressed in many metastatic tumors. The study's results suggest that TTX-MC138 may have potential applicability across additional metastatic disease settings beyond breast cancer.
Dr. Daniel J. O'Mahony, President and CEO of TransCode, commented, "These data provide strong evidence that our lead candidate can effectively home to metastatic lesions and produce meaningful therapeutic benefit. The survival advantage observed in this aggressive model of bone metastasis is particularly encouraging and supports our belief that TTX-MC138 has the potential to become a cornerstone treatment for metastatic cancer."
The study's significance lies in the fact that bone metastasis is a common and serious complication of advanced breast cancer, often leading to significant morbidity and mortality. Current treatment options for bone metastases are limited, and there is a high unmet need for effective therapies. If these preclinical results translate to the clinical setting, TTX-MC138 could offer a new treatment option for patients with advanced disease.
TransCode Therapeutics is focused on developing first-in-class therapeutics for high-risk and advanced cancers. Beyond TTX-MC138, the company has a portfolio of other therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The positive results from this study add to the growing body of evidence supporting the company's platform and its potential to address challenging metastatic cancers.
The full press release is available at https://ibn.fm/E6gbq. For more information about TransCode Therapeutics, please visit the company's newsroom at https://ibn.fm/RNAZ.
